ID

12805

Beskrivning

Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL); ODM derived from: https://clinicaltrials.gov/show/NCT01506453

Länk

https://clinicaltrials.gov/show/NCT01506453

Nyckelord

  1. 2015-12-21 2015-12-21 -
Uppladdad den

21 december 2015

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0

Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Acute Lymphoblastic Leukemia NCT01506453

Eligibility Acute Lymphoblastic Leukemia NCT01506453

Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
participant is enrolled on total xvi
Beskrivning

total xvi protocol

Datatyp

boolean

Alias
UMLS CUI [1]
C0949634
participant is 1 year of age or older
Beskrivning

age

Datatyp

boolean

Alias
UMLS CUI [1]
C0001779
participant has symptoms of np/pn with onset no more than 7 days after one of the following vincristine doses: protocol week 1, week 2 (induction), week 7 (reinduction i), or week 17 (reinduction ii).
Beskrivning

neuropathic pain

Datatyp

boolean

Alias
UMLS CUI [1]
C0458960
patient is expected to receive 2 doses of vincristine in weekly intervals as outlined by the total xvi protocol while on study drug (i.e. no known dosage reductions or planned missed doses).
Beskrivning

treatment protocol

Datatyp

boolean

Alias
UMLS CUI [1]
C0949634
participant is able and willing to take oral medications.
Beskrivning

compliance

Datatyp

boolean

Alias
UMLS CUI [1]
C1321605
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
previous participation in this study
Beskrivning

study subject participation status

Datatyp

boolean

Alias
UMLS CUI [1]
C2348568
participant is receiving gabapentin for another indication at the time of diagnosis of np/pn or has received gabapentin previously.
Beskrivning

participant is receiving gabapentin for another indication

Datatyp

boolean

Alias
UMLS CUI [1]
C0060926
UMLS CUI [2]
C0087111
pregnancy. female participants of childbearing potential must have documented negative urine or serum pregnancy test result not older than 7 days. male patients with reproductive potential will be counseled not to procreate during the study.
Beskrivning

pregnancy test negative , Contraception

Datatyp

boolean

Alias
UMLS CUI [1]
C0427780
UMLS CUI [2]
C0700589
impaired renal function: decreased egfr (<60ml/min/1.73m^2 as estimated by the revised schwartz equation)
Beskrivning

impaired renal function

Datatyp

boolean

Alias
UMLS CUI [1]
C0151746
participant has allergy or other contraindication for either morphine or gabapentin therapy.
Beskrivning

participant has allergy or other contraindication for either morphine or gabapentin therapy

Datatyp

boolean

Alias
UMLS CUI [1]
C0020517
UMLS CUI [2]
C0026549
UMLS CUI [3]
C0060926
inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
Beskrivning

informed consent

Datatyp

boolean

Alias
UMLS CUI [1]
C0021430

Similar models

Eligibility Acute Lymphoblastic Leukemia NCT01506453

Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
total xvi protocol
Item
participant is enrolled on total xvi
boolean
C0949634 (UMLS CUI [1])
age
Item
participant is 1 year of age or older
boolean
C0001779 (UMLS CUI [1])
neuropathic pain
Item
participant has symptoms of np/pn with onset no more than 7 days after one of the following vincristine doses: protocol week 1, week 2 (induction), week 7 (reinduction i), or week 17 (reinduction ii).
boolean
C0458960 (UMLS CUI [1])
treatment protocol
Item
patient is expected to receive 2 doses of vincristine in weekly intervals as outlined by the total xvi protocol while on study drug (i.e. no known dosage reductions or planned missed doses).
boolean
C0949634 (UMLS CUI [1])
compliance
Item
participant is able and willing to take oral medications.
boolean
C1321605 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
study subject participation status
Item
previous participation in this study
boolean
C2348568 (UMLS CUI [1])
participant is receiving gabapentin for another indication
Item
participant is receiving gabapentin for another indication at the time of diagnosis of np/pn or has received gabapentin previously.
boolean
C0060926 (UMLS CUI [1])
C0087111 (UMLS CUI [2])
pregnancy test negative , Contraception
Item
pregnancy. female participants of childbearing potential must have documented negative urine or serum pregnancy test result not older than 7 days. male patients with reproductive potential will be counseled not to procreate during the study.
boolean
C0427780 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
impaired renal function
Item
impaired renal function: decreased egfr (<60ml/min/1.73m^2 as estimated by the revised schwartz equation)
boolean
C0151746 (UMLS CUI [1])
participant has allergy or other contraindication for either morphine or gabapentin therapy
Item
participant has allergy or other contraindication for either morphine or gabapentin therapy.
boolean
C0020517 (UMLS CUI [1])
C0026549 (UMLS CUI [2])
C0060926 (UMLS CUI [3])
informed consent
Item
inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
boolean
C0021430 (UMLS CUI [1])

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial